Skip to main content
PMC home page
Applied Microbiology logoLink to Applied Microbiology
. 1971 Jan;21(1):61–65. doi: 10.1128/am.21.1.61-65.1971

In Vitro Studies of α-Carboxyl-3-Thienylmethyl Penicillin, a New Semisynthetic Penicillin

Gerald P Bodey 1, Beverly Deerhake 1
PMCID: PMC377117  PMID: 4924999

Abstract

The activity of a new semisynthetic penicillin, α-carboxyl-3-thienylmethyl penicillin (BRL-2288) was determined against 535 clinical isolates of gram-negative bacilli, by using the tube dilution technique. Nearly 80% of isolates of Proteus spp. were inhibited by 3.12 μg or less of this antibiotic per ml. BRL-2288 was as active as ampicillin against Escherichia coli. It was slightly more active than carbenicillin or 6-(d-α-sulfoaminophenylacetamido)-penicillanic acid against Pseudomonas sp., with over half of the isolates being inhibited by 50 μg or less of BRL-2288 per ml. Isolates of Klebsiella sp. were routinely resistant to this antibiotic. The drug was bactericidal against most sensitive organisms. BRL-2288 was less active against large inocula. A strain of Pseudomonas sp. which developed resistance to carbenicillin also developed resistance to BRL-2288 simultaneously.

Full text

PDF
61

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acred P., Brown D. M., Knudsen E. T., Rolinson G. N., Sutherland R. New semi-synthetic penicillin active against Pseudomonas pyocyanea. Nature. 1967 Jul 1;215(5096):25–30. doi: 10.1038/215025a0. [DOI] [PubMed] [Google Scholar]
  2. Altemeier W. A., Todd J. C., Inge W. W. Gram-negative septicemia: a growing threat. Ann Surg. 1967 Oct;166(4):530–542. doi: 10.1097/00000658-196710000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bell S. M., Smith D. D. Resistance of Pseudomonas aeruginosa to carbenicillin. Lancet. 1969 Apr 12;1(7598):753–754. doi: 10.1016/s0140-6736(69)91754-1. [DOI] [PubMed] [Google Scholar]
  4. Bodey G. P., Rodriguez V., Luce J. K. Carbenicillin therapy of gram-negative bacilli infections. Am J Med Sci. 1969 Jun;257(6):408–414. doi: 10.1097/00000441-196906000-00007. [DOI] [PubMed] [Google Scholar]
  5. Bodey G. P., Rodriguez V. Preliminary studies of 6-(D-alpha-sulfoaminophenylacetamido) penicillanic acid (BL-P1462) in the treatment of Pseudomonas infections. Curr Ther Res Clin Exp. 1970 Jun;12(6):363–368. [PubMed] [Google Scholar]
  6. Bodey G. P., Rodriguez V., Smith J. P. Serratia sp. infections in cancer patients. Cancer. 1970 Jan;25(1):199–205. doi: 10.1002/1097-0142(197001)25:1<199::aid-cncr2820250128>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  7. Bodey G. P., Stewart D. In vitro studies of a new semisynthetic penicillin, 6-(d-alpha-sulfoaminophenylacetamido)-penicillanic acid. Appl Microbiol. 1969 Jul;18(1):76–79. doi: 10.1128/am.18.1.76-79.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Brumfitt W., Percival A., Leigh D. A. Clinical and laboratory studies with carbenicillin. A new penicillin active against Pseudomonas pyocyanea. Lancet. 1967 Jun 17;1(7503):1289–1293. doi: 10.1016/s0140-6736(67)91590-5. [DOI] [PubMed] [Google Scholar]
  9. Darrell J. H., Waterworth P. M. Carbenicillin resistance in Pseudomonas aeruginosa from clinical material. Br Med J. 1969 Jul 19;3(5663):141–143. doi: 10.1136/bmj.3.5663.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. DuPont H. L., Spink W. W. Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) 1969 Jul;48(4):307–332. doi: 10.1097/00005792-196907000-00003. [DOI] [PubMed] [Google Scholar]
  11. Edmondson E. B., Sanford J. P. The Klebsiella-Enterobacter (Aerobacter)-Serratia group. A clinical and bacteriological evaluation. Medicine (Baltimore) 1967 Jul;46(4):323–340. doi: 10.1097/00005792-196707000-00002. [DOI] [PubMed] [Google Scholar]
  12. Freid M. A., Vosti K. L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968 May;121(5):418–423. [PubMed] [Google Scholar]
  13. HERSH E. M., BODEY G. P., NIES B. A., FREIREICH E. J. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA. 1965 Jul 12;193:105–109. doi: 10.1001/jama.1965.03090020019005. [DOI] [PubMed] [Google Scholar]
  14. Hoffman T. A., Bullock W. E. Carbenicillin therapy of Pseudomonas and other gram-negative bacillary infections. Ann Intern Med. 1970 Aug;73(2):165–171. doi: 10.7326/0003-4819-73-2-165. [DOI] [PubMed] [Google Scholar]
  15. Lowbury E. J., Lilly H. A., Kidson A., Ayliffe G. A., Jones R. J. Sensitivity of Pseudomonas aeruginosa to antibiotics: emergence of strains highly resistant to carbenicillin. Lancet. 1969 Aug 30;2(7618):448–452. doi: 10.1016/s0140-6736(69)90163-9. [DOI] [PubMed] [Google Scholar]
  16. Marks M. I., Eickhoff T. C. Carbenicillin: a clinical and laboratory evaluation. Ann Intern Med. 1970 Aug;73(2):179–187. doi: 10.7326/0003-4819-73-2-179. [DOI] [PubMed] [Google Scholar]
  17. Price K. E., Chisholm D. R., Leitner F., Misiek M., Gourevitch A. Antipseudomonal activity of alpha-sulfoaminopenicillins. Appl Microbiol. 1969 Jun;17(6):881–887. doi: 10.1128/am.17.6.881-887.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. RABIN E. R., GRABER C. D., VOGEL E. H., Jr, FINKELSTEIN R. A., TUMBUSCH W. A. Fatal pseudomonas infection in burned patients. A clinical, bacteriologic and anatomic study. N Engl J Med. 1961 Dec 21;265:1225–1231. doi: 10.1056/NEJM196112212652501. [DOI] [PubMed] [Google Scholar]
  19. Rodriguez V., Whitecar J. P., Jr, Bodey G. P. Therapy of infections with the combination of carbenicillin and gentamicin. Antimicrob Agents Chemother (Bethesda) 1969;9:386–390. [PubMed] [Google Scholar]
  20. Stratford B. C. The treatment of infections due to Pseudomonas aeruginosa with carbenicillin ("Pyopen"). Med J Aust. 1968 Nov 16;2(20):890–895. doi: 10.5694/j.1326-5377.1968.tb83274.x. [DOI] [PubMed] [Google Scholar]

Articles from Applied Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES